Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
News|Articles|September 1, 2026
FDA updates in urology: August 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from August 2026.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! This month’s regulatory news featured new device and drug developments across benign and oncologic urology care, including 2 advances that build on existing therapeutic platforms.
Related to this article
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
A decision is expected by the fourth quarter of 2026.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.
All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.
Advertisement
Advertisement